1Alexander WS. Suppressors of eytokine signaling (SOCS) in the immune system. Nat Rev Immunol, 2002, 2: 410-416.
2Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits Jak kinases. Nature, 1997, 387:921-924.
3Hilton DJ, Richardson RT, Alexander WS, et al. Twenty proteins containing a C-terminal SOCS box form five structural classes.Proc Natl Acad Sci USA, 1998, 95: 114-119.
4Sengupta TK, Chen A, Zhong Z, et al. Activation of monocyte effector genes and Stat family transcription factors by inflammatory synovial fluid is independent of interferon gamma. J Exp Med,1995, 181: 1015-1025.
5Kasperkovitz PV, Verbeet NL, Smeets TJ, et al. Activation of the Statl pathway in rheumatoid arthritis. Ann Rheum Dis, 2004, 63:233-239.
6Gil MP, Bohn E, O'Guin AK, et al. Biologic consequences of Statl-independent IFN signaling. Proc Natl Acad Sci USA, 2001,98: 6680-6685.
7Ramana CV, Gil MP, Han Y, et al. Statl-independent regulation of gene expression in response to IFN-gamma. Proc Natl Acad Sci USA, 2001, 98: 6674-6679.
8Krause A, Scaletta N, Ji JD, et al. Rheumatoid arthritis synoviocyte survival is dependent on Stat3. J Immunol, 2002,169:6610-6616.
9Shouda T, Yoshida T, Hanada T, et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest, 2001, 108: 1781.
10De Hooge AS, van de Loo FA, Koenders MI, et al. Local activation of Statl and Stat3 in the inflamed synovium during zymosaninduced arthritis: exacerbation of joint inflammation in Statl gene-knockout mice. Arthritis Rheum, 2004, 50: 2014-2023.
